<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250124051139
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250124051139" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 24 Jan 2025 10:11:40 +0000</lastbuilddate>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Integration of 168,000 samples reveals global patterns of the human gut microbiome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39848248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>The factors shaping human microbiome variation are a major focus of biomedical research. While other fields have used large sequencing compendia to extract insights requiring otherwise impractical sample sizes, the microbiome field has lacked a comparably sized resource for the 16S rRNA gene amplicon sequencing commonly used to quantify microbiome composition. To address this gap, we processed 168,464 publicly available human gut microbiome samples with a uniform pipeline. We use this compendium...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 16:S0092-8674(24)01430-2. doi: 10.1016/j.cell.2024.12.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The factors shaping human microbiome variation are a major focus of biomedical research. While other fields have used large sequencing compendia to extract insights requiring otherwise impractical sample sizes, the microbiome field has lacked a comparably sized resource for the 16S rRNA gene amplicon sequencing commonly used to quantify microbiome composition. To address this gap, we processed 168,464 publicly available human gut microbiome samples with a uniform pipeline. We use this compendium to evaluate geographic and technical effects on microbiome variation. We find that regions such as Central and Southern Asia differ significantly from the more thoroughly characterized microbiomes of Europe and Northern America and that composition alone can be used to predict a sample's region of origin. We also find strong associations between microbiome variation and technical factors such as primers and DNA extraction. We anticipate this growing work, the Human Microbiome Compendium, will enable advanced applied and methodological research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39848248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39848248</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.017>10.1016/j.cell.2024.12.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39848248</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Richard J Abdill</dc:creator>
<dc:creator>Samantha P Graham</dc:creator>
<dc:creator>Vincent Rubinetti</dc:creator>
<dc:creator>Mansooreh Ahmadian</dc:creator>
<dc:creator>Parker Hicks</dc:creator>
<dc:creator>Ashwin Chetty</dc:creator>
<dc:creator>Daniel McDonald</dc:creator>
<dc:creator>Pamela Ferretti</dc:creator>
<dc:creator>Elizabeth Gibbons</dc:creator>
<dc:creator>Marco Rossi</dc:creator>
<dc:creator>Arjun Krishnan</dc:creator>
<dc:creator>Frank W Albert</dc:creator>
<dc:creator>Casey S Greene</dc:creator>
<dc:creator>Sean Davis</dc:creator>
<dc:creator>Ran Blekhman</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Integration of 168,000 samples reveals global patterns of the human gut microbiome</dc:title>
<dc:identifier>pmid:39848248</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.017</dc:identifier>
</item>
<item>
<title>Massively parallel reporter assay investigates shared genetic variants of eight psychiatric disorders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39848247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>A meta-genome-wide association study across eight psychiatric disorders has highlighted the genetic architecture of pleiotropy in major psychiatric disorders. However, mechanisms underlying pleiotropic effects of the associated variants remain to be explored. We conducted a massively parallel reporter assay to decode the regulatory logic of variants with pleiotropic and disorder-specific effects. Pleiotropic variants differ from disorder-specific variants by exhibiting chromatin accessibility...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 20:S0092-8674(24)01435-1. doi: 10.1016/j.cell.2024.12.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A meta-genome-wide association study across eight psychiatric disorders has highlighted the genetic architecture of pleiotropy in major psychiatric disorders. However, mechanisms underlying pleiotropic effects of the associated variants remain to be explored. We conducted a massively parallel reporter assay to decode the regulatory logic of variants with pleiotropic and disorder-specific effects. Pleiotropic variants differ from disorder-specific variants by exhibiting chromatin accessibility that extends across diverse cell types in the neuronal lineage and by altering motifs for transcription factors with higher connectivity in protein-protein interaction networks. We mapped pleiotropic and disorder-specific variants to putative target genes using functional genomics approaches and CRISPR perturbation. In vivo CRISPR perturbation of a pleiotropic and a disorder-specific gene suggests that pleiotropy may involve the regulation of genes expressed broadly across neuronal cell types and with higher network connectivity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39848247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39848247</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.022>10.1016/j.cell.2024.12.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39848247</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sool Lee</dc:creator>
<dc:creator>Jessica C McAfee</dc:creator>
<dc:creator>Jiseok Lee</dc:creator>
<dc:creator>Alejandro Gomez</dc:creator>
<dc:creator>Austin T Ledford</dc:creator>
<dc:creator>Declan Clarke</dc:creator>
<dc:creator>Hyunggyu Min</dc:creator>
<dc:creator>Mark B Gerstein</dc:creator>
<dc:creator>Alan P Boyle</dc:creator>
<dc:creator>Patrick F Sullivan</dc:creator>
<dc:creator>Adriana S Beltran</dc:creator>
<dc:creator>Hyejung Won</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Massively parallel reporter assay investigates shared genetic variants of eight psychiatric disorders</dc:title>
<dc:identifier>pmid:39848247</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.022</dc:identifier>
</item>
<item>
<title>Receptor binding, structure, and tissue tropism of cattle-infecting H5N1 avian influenza virus hemagglutinin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39848246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>The ongoing circulation of highly pathogenic avian influenza (HPAI) A (H5N1) viruses, particularly clade 2.3.4.4b strains, poses a significant threat to animal and public health. Recent outbreaks in cattle highlight concerns about cross-species transmission and zoonotic spillover. Here, we found that the hemagglutinin (HA) protein from a cattle-infecting H5N1 virus has acquired slight binding to human-like α2-6-linked receptors while still exhibiting a strong preference for avian-like...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 22:S0092-8674(25)00048-0. doi: 10.1016/j.cell.2025.01.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The ongoing circulation of highly pathogenic avian influenza (HPAI) A (H5N1) viruses, particularly clade 2.3.4.4b strains, poses a significant threat to animal and public health. Recent outbreaks in cattle highlight concerns about cross-species transmission and zoonotic spillover. Here, we found that the hemagglutinin (HA) protein from a cattle-infecting H5N1 virus has acquired slight binding to human-like α2-6-linked receptors while still exhibiting a strong preference for avian-like α2-3-linked sialic acid receptors. Immunohistochemical staining revealed HA binding to bovine pulmonary and mammary tissues, aligning with clinical observations. HA also binds effectively to human conjunctival, tracheal, and mammary tissues, indicating a risk for human transmission, notably in cases of conjunctivitis. High-resolution cryo-electron microscopy (cryo-EM) structures of this H5 HA in complex with either α2-3 or α2-6 receptors elucidate the molecular mechanisms underlying its receptor-binding properties. These findings provide critical insights into the tropism and transmission potential of this emerging pathogen.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39848246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39848246</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.019>10.1016/j.cell.2025.01.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39848246</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Hao Song</dc:creator>
<dc:creator>Tianjiao Hao</dc:creator>
<dc:creator>Pu Han</dc:creator>
<dc:creator>Haichen Wang</dc:creator>
<dc:creator>Xu Zhang</dc:creator>
<dc:creator>Xiaomei Li</dc:creator>
<dc:creator>Yuxuan Wang</dc:creator>
<dc:creator>Jiamin Chen</dc:creator>
<dc:creator>Ying Li</dc:creator>
<dc:creator>Xiyue Jin</dc:creator>
<dc:creator>Xuefeng Duan</dc:creator>
<dc:creator>Wei Zhang</dc:creator>
<dc:creator>Yuhai Bi</dc:creator>
<dc:creator>Ronghua Jin</dc:creator>
<dc:creator>Lei Sun</dc:creator>
<dc:creator>Ningli Wang</dc:creator>
<dc:creator>George F Gao</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Receptor binding, structure, and tissue tropism of cattle-infecting H5N1 avian influenza virus hemagglutinin</dc:title>
<dc:identifier>pmid:39848246</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.019</dc:identifier>
</item>
<item>
<title>The relationship between cannabis and cardiovascular disease: clearing the haze</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39849111/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>Cannabis has been consumed for centuries, but global regulatory changes over the past three decades have increased the availability and consumption of cannabis. Cannabinoids are touted to have therapeutic potential for many diseases and could be a replacement for opioids for analgesia and sedation. However, cannabinoids can cause substantial adverse cardiovascular events that would mitigate any potential benefit. The endocannabinoid system regulates mood, satiety and memory, and modulates the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 23. doi: 10.1038/s41569-025-01121-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cannabis has been consumed for centuries, but global regulatory changes over the past three decades have increased the availability and consumption of cannabis. Cannabinoids are touted to have therapeutic potential for many diseases and could be a replacement for opioids for analgesia and sedation. However, cannabinoids can cause substantial adverse cardiovascular events that would mitigate any potential benefit. The endocannabinoid system regulates mood, satiety and memory, and modulates the cardiovascular system. The link between cannabinoids and cardiovascular disease, which used to be limited to evidence from preclinical studies, case reports and case series, is now evident in epidemiological studies. Cannabinoids adversely affect the cardiovascular system, causing myocardial infarction, cerebrovascular accidents, arrhythmia and heart failure. The effects of novel cannabinoids are unknown, and synthetic cannabinoids have the potential to cause even more substantial harm than traditional cannabinoids. Therefore, with the increasing availability and use of cannabis, the acute and chronic effects of this drug are becoming apparent.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39849111/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39849111</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01121-6>10.1038/s41569-025-01121-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39849111</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Mark Chandy</dc:creator>
<dc:creator>Nerea Jimenez-Tellez</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The relationship between cannabis and cardiovascular disease: clearing the haze</dc:title>
<dc:identifier>pmid:39849111</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01121-6</dc:identifier>
</item>
<item>
<title>Fatal coronary embolism in infective endocarditis: a case of sudden circulatory collapse</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39847400/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 23:ehaf014. doi: 10.1093/eurheartj/ehaf014. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39847400/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39847400</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf014>10.1093/eurheartj/ehaf014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39847400</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Shinichi Yamanaka</dc:creator>
<dc:creator>Hideaki Suzuki</dc:creator>
<dc:creator>Satoshi Yasuda</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fatal coronary embolism in infective endocarditis: a case of sudden circulatory collapse</dc:title>
<dc:identifier>pmid:39847400</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf014</dc:identifier>
</item>
<item>
<title>Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39846939/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 16:S0735-1097(24)10558-X. doi: 10.1016/j.jacc.2024.10.126. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39846939/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39846939</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.126>10.1016/j.jacc.2024.10.126</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39846939</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Richard K Cheng</dc:creator>
<dc:creator>Douglas Leedy</dc:creator>
<dc:creator>Frederick L Ruberg</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis?</dc:title>
<dc:identifier>pmid:39846939</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.126</dc:identifier>
</item>
<item>
<title>Associations of Short-Term Ozone Exposure With Hypoxia and Arterial Stiffness</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39846938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: O(3) exposure may reduce oxygen availability, prompting compensatory increases in red blood cells and hemoglobin, which exacerbate arterial stiffening. These findings provide new insights into the mechanisms underlying O(3)-induced cardiovascular injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 16:S0735-1097(24)10559-1. doi: 10.1016/j.jacc.2024.11.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Epidemiological studies reported associations between ozone (O<sub>3</sub>) exposure and cardiovascular diseases, yet the biological mechanisms remain underexplored. Hypoxia is a shared pathogenesis of O<sub>3</sub>-associated diseases; therefore, we hypothesized that O<sub>3</sub> exposure may induce changes in hypoxia-related markers, leading to adverse cardiovascular effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to investigate associations of short-term O<sub>3</sub> exposure with hypoxic biomarkers and arterial stiffness.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a panel study involving 210 young healthy residents in 2 cities at different altitudes on the Qinghai-Tibetan Plateau in China, where O<sub>3</sub> concentrations are high and particulate pollution is low. Participants underwent 4 repeated visits to assess ambient O<sub>3</sub> exposure levels, hypoxic biomarkers, and arterial stiffness. We applied linear mixed-effects models to assess the associations of O<sub>3</sub> exposure (lag1 to lag1-7 days) with hypoxic biomarkers and arterial stiffness, adjusted for confounders. Mediation analyses explored the hypoxia's role in O<sub>3</sub>-related arterial stiffness changes. We further examined effect modification by residence altitude and the robustness of results by including PM<sub>2.5</sub> (particulate matter ≤2.5 μm in aerodynamic diameter) or NO<sub>2</sub> in 2-pollutant models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: O<sub>3</sub> exposure 1 to 7 days before visits was significantly associated with changes in multiple hypoxic biomarkers. A 10-ppb increase in O<sub>3</sub> exposure was linked to significant decreases in oxygen saturation (SpO<sub>2</sub>) and increases in red blood cell count (RBC), hemoglobin concentration, and hematocrit, with maximum changes by -0.42%, 0.92%, 0.97%, and 1.92%, respectively. Laboratory analysis of mRNA and protein markers consistently indicated that O<sub>3</sub> exposure activated the hypoxia-inducible factor 1 (HIF-1) signaling pathway. Additionally, a 10-ppb increase in O<sub>3</sub> corresponded to a 1.04% to 1.33% increase in carotid-femoral pulse wave velocity (cfPWV), indicating increased arterial stiffness. RBC, hemoglobin concentration, and hematocrit increases significantly mediated the O<sub>3</sub>-cfPWV association, whereas the SpO<sub>2</sub> reduction had an insignificant mediating effect. Associations of O<sub>3</sub> with hypoxic biomarkers varied by altitude. The higher altitude group showed delayed associations with SpO₂ and HIF-1 expression but stronger associations with RBC indices. These associations remained robust after adjusting for copollutants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: O<sub>3</sub> exposure may reduce oxygen availability, prompting compensatory increases in red blood cells and hemoglobin, which exacerbate arterial stiffening. These findings provide new insights into the mechanisms underlying O<sub>3</sub>-induced cardiovascular injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39846938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39846938</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.044>10.1016/j.jacc.2024.11.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39846938</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Qiaoyi Hua</dc:creator>
<dc:creator>Xin Meng</dc:creator>
<dc:creator>Wu Chen</dc:creator>
<dc:creator>Yifan Xu</dc:creator>
<dc:creator>Ruiwei Xu</dc:creator>
<dc:creator>Yunxiu Shi</dc:creator>
<dc:creator>Jiajianghui Li</dc:creator>
<dc:creator>Xueling Meng</dc:creator>
<dc:creator>Ailin Li</dc:creator>
<dc:creator>Qianqian Chai</dc:creator>
<dc:creator>Mengshuang Sheng</dc:creator>
<dc:creator>Yuan Yao</dc:creator>
<dc:creator>Yunfei Fan</dc:creator>
<dc:creator>Ruohong Qiao</dc:creator>
<dc:creator>Yi Zhang</dc:creator>
<dc:creator>Teng Wang</dc:creator>
<dc:creator>Yidan Zhang</dc:creator>
<dc:creator>Xiaoyu Cui</dc:creator>
<dc:creator>Yaqi Yu</dc:creator>
<dc:creator>Haonan Li</dc:creator>
<dc:creator>Rui Tang</dc:creator>
<dc:creator>Meilin Yan</dc:creator>
<dc:creator>Bu Duo</dc:creator>
<dc:creator>Danzeng Dunzhu</dc:creator>
<dc:creator>Zhuo Ga</dc:creator>
<dc:creator>Lei Hou</dc:creator>
<dc:creator>Yingjun Liu</dc:creator>
<dc:creator>Jing Shang</dc:creator>
<dc:creator>Qi Chen</dc:creator>
<dc:creator>Xinghua Qiu</dc:creator>
<dc:creator>Chunxiang Ye</dc:creator>
<dc:creator>Jicheng Gong</dc:creator>
<dc:creator>Tong Zhu</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Associations of Short-Term Ozone Exposure With Hypoxia and Arterial Stiffness</dc:title>
<dc:identifier>pmid:39846938</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.044</dc:identifier>
</item>
<item>
<title>The Pathogenetic Link Between Ozone Pollution and Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39846937/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 17:S0735-1097(24)10658-4. doi: 10.1016/j.jacc.2024.12.011. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39846937/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39846937</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.011>10.1016/j.jacc.2024.12.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39846937</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexandra Schneider</dc:creator>
<dc:creator>Kai Chen</dc:creator>
<dc:creator>Susanne Breitner</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Pathogenetic Link Between Ozone Pollution and Cardiovascular Disease</dc:title>
<dc:identifier>pmid:39846937</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.011</dc:identifier>
</item>
<item>
<title>Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39846936/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: During APOLLO-B, outpatient worsening HF in patients with transthyretin amyloidosis with cardiomyopathy was frequent, prognostic, and reduced by patisiran.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 16:S0735-1097(24)10297-5. doi: 10.1016/j.jacc.2024.10.097. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Outpatient worsening heart failure (HF), defined by initiation or intensification of diuretics, is adversely prognostic for patients with either reduced or preserved ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to investigate the prognostic value of outpatient worsening HF in transthyretin amyloidosis with cardiomyopathy and the effect of patisiran treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Post hoc analyses of the APOLLO-B trial (NCT03997383) evaluated the associations between outpatient worsening HF (defined by oral diuretic initiation or intensification), measures of disease progression, and a composite endpoint of all-cause mortality and cardiovascular (CV) events. We further examined the effect of patisiran on outpatient worsening HF over 24 months (ie, during the double-blind and open-label extension periods).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In APOLLO-B, 144 (40.1%) patients had no event, 157 (43.7%) had outpatient worsening HF, 13 (3.6%) required an urgent HF visit, 118 (32.9%) had a CV hospitalization, and 47 (13.1%) died. Outpatient worsening HF was associated with an increased risk of all-cause mortality and CV events (HR: 2.21; 95% CI: 1.58-3.08), as well as a greater deterioration in 6-minute walk test distance, Kansas City Cardiomyopathy Questionnaire-Overall Summary score, and NYHA functional class and a greater increase in N-terminal prohormone of B-type natriuretic peptide. Addition of outpatient diuretic initiation or intensification to the composite endpoint of all-cause mortality and CV events increased the overall number of patients having an event from 141 to 215 (a 52% increase). Patisiran reduced the risk of outpatient worsening HF (HR: 0.70; 95% CI: 0.51-0.96) over 24 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: During APOLLO-B, outpatient worsening HF in patients with transthyretin amyloidosis with cardiomyopathy was frequent, prognostic, and reduced by patisiran.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39846936/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39846936</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.097>10.1016/j.jacc.2024.10.097</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39846936</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Marianna Fontana</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Shaun Bender</dc:creator>
<dc:creator>Patrick Y Jay</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial</dc:title>
<dc:identifier>pmid:39846936</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.097</dc:identifier>
</item>
<item>
<title>NEDD4-Mediated GSNOR Degradation Aggravates Cardiac Hypertrophy and Dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39846173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings showed that upregulated NEDD4 leads to GSNOR ubiquitination and subsequent degradation, thereby facilitating the progression of cardiac hypertrophy. NEDD4 inhibitors may serve as a potential therapeutic strategy for the treatment of cardiac hypertrophy and heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 23. doi: 10.1161/CIRCRESAHA.124.324872. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The decrease in S-nitrosoglutathione reductase (GSNOR) leads to an elevation of S-nitrosylation, thereby exacerbating the progression of cardiomyopathy in response to hemodynamic stress. However, the mechanisms under GSNOR decrease remain unclear. Here, we identify NEDD4 (neuronal precursor cell expressed developmentally downregulated 4) as a novel molecule that plays a crucial role in the pathogenesis of pressure overload-induced cardiac hypertrophy, by modulating GSNOR levels, thereby demonstrating significant therapeutic potential.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Protein synthesis and degradation inhibitors were used to verify the reasons for the decrease in GSNOR. Mass spectrometry and database filtering were used to uncover NEDD4, the E3 Ub (ubiquitin) ligase, involved in GSNOR decrease. NEDD4 cardiomyocyte-specific deficiency mice were used to evaluate the role of NEDD4 and NEDD4-induced ubiquitination of GSNOR in cardiac hypertrophy in vivo. Both IBM, a highly specific NEDD4 inhibitor, and indole-3-carbinol, a NEDD4 inhibitor currently undergoing phase 2 clinical trial, were used to effectively suppress the NEDD4/GSNOR axis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: GSNOR protein levels were reduced, while mRNA levels remained unchanged in myocardium samples from hypertrophic patients and transverse aortic constriction-induced mice, indicating GSNOR is regulated by ubiquitination. NEDD4, an E3 Ub ligase, was associated with GSNOR ubiquitination, which exhibited significantly higher expression levels in hypertrophic myocardial samples. Moreover, either the NEDD4 enzyme-dead mutant or GSNOR nonubiquitylated mutant decreased GSNOR ubiquitination and inhibited cardiac hypertrophic growth. Cardiomyocyte-specific NEDD4 deficiency inhibited cardiac hypertrophy in vitro and in vivo. NEDD4 inhibitor IBM effectively suppressed GSNOR ubiquitination and cardiac hypertrophy. Clinically, indole-3-carbinol, a NEDD4 inhibitor in phase II clinical trials used as an antitumor drug, demonstrated comparable efficacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings showed that upregulated NEDD4 leads to GSNOR ubiquitination and subsequent degradation, thereby facilitating the progression of cardiac hypertrophy. NEDD4 inhibitors may serve as a potential therapeutic strategy for the treatment of cardiac hypertrophy and heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39846173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39846173</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324872>10.1161/CIRCRESAHA.124.324872</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39846173</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Xin Tang</dc:creator>
<dc:creator>Xiameng Liu</dc:creator>
<dc:creator>Xinqi Sha</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Yan Zu</dc:creator>
<dc:creator>Qiyao Fan</dc:creator>
<dc:creator>Lulu Hu</dc:creator>
<dc:creator>Shixiu Sun</dc:creator>
<dc:creator>Zhiren Zhang</dc:creator>
<dc:creator>Feng Chen</dc:creator>
<dc:creator>ChengHui Yan</dc:creator>
<dc:creator>Xin Chen</dc:creator>
<dc:creator>Yueyue Xu</dc:creator>
<dc:creator>Wen Chen</dc:creator>
<dc:creator>Yongfeng Shao</dc:creator>
<dc:creator>Jiaxi Gu</dc:creator>
<dc:creator>Jun Pu</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:creator>Yaling Han</dc:creator>
<dc:creator>Liping Xie</dc:creator>
<dc:creator>Yi Han</dc:creator>
<dc:creator>Yong Ji</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>NEDD4-Mediated GSNOR Degradation Aggravates Cardiac Hypertrophy and Dysfunction</dc:title>
<dc:identifier>pmid:39846173</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324872</dc:identifier>
</item>
<item>
<title>Placental Hypoxia-Induced Ferroptosis Drives Vascular Damage in Preeclampsia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39846172/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In pregnancy, iron and oxygen work synergistically to conserve an operative antioxidant system to maintain iron homeostasis and protect the placenta from ferroptotic death. Hindrance to this system due to hypoxia results in heightened ferroptosis rates and sEV-mediated extrusion of harmful lipid peroxides from trophoblast cells into the circulation thereby contributing to maternal endothelial dysfunction characterizing preeclampsia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 23. doi: 10.1161/CIRCRESAHA.124.325119. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Iron is an essential micronutrient for cell survival and growth; however, excess of this metal drives ferroptosis. Although maternal iron imbalance and placental hypoxia are independent contributors to the pathogenesis of preeclampsia, a hypertensive disorder of pregnancy, the mechanisms by which their interaction impinge on maternal and placental health remain elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used placentae from normotensive and preeclampsia pregnancy cohorts, human H9 embryonic stem cells differentiated into cytotrophoblast-like cells, and placenta-specific <i>Phd2</i><sup><i>-/-</i></sup> preeclamptic mice. Lipid peroxidation and iron cargo of placenta-derived small extracellular vesicles (sEVs) isolated from the maternal circulation of control and preeclampsia individuals were examined by mass spectrometry, flow cytometry, and colorimetry. Human microvascular endothelial cells' angiogenic capacity and function were examined after exposure to control and pathological sEVs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Placentae from preeclampsia pregnancies contain increased ferrous iron and lipid peroxidation byproduct, malondialdehyde. Antioxidant capacity is significantly lower in preeclampsia placentae, with decreased glutathione content, and GPx4 (glutathione peroxidase 4) expression and activity. Hypoxia triggers the occurrence of ferroptosis in human trophoblast cells and mouse <i>Phd2</i><sup><i>-</i></sup><sup><i>/-</i></sup>placentae. Disrupted placental iron homeostasis in preeclampsia is accompanied by improper extrusion of iron through sEVs mediated by the pentaspan protein prominin-2. Heightened lipid peroxidation content was found in villous explants and maternal circulating sEVs of preeclampsia individuals. Exposure of human microvascular endothelial cells to preeclampsia-derived placental sEVs results in endothelial activation and impaired angiogenesis, which is rescued by treatment with hinokitiol, a compound known to restore tissue iron balance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In pregnancy, iron and oxygen work synergistically to conserve an operative antioxidant system to maintain iron homeostasis and protect the placenta from ferroptotic death. Hindrance to this system due to hypoxia results in heightened ferroptosis rates and sEV-mediated extrusion of harmful lipid peroxides from trophoblast cells into the circulation thereby contributing to maternal endothelial dysfunction characterizing preeclampsia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39846172/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39846172</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325119>10.1161/CIRCRESAHA.124.325119</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39846172</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Chanho Park</dc:creator>
<dc:creator>Sruthi Alahari</dc:creator>
<dc:creator>Jonathan W Ausman</dc:creator>
<dc:creator>Ruizhe Liu</dc:creator>
<dc:creator>Frederik Nguyen</dc:creator>
<dc:creator>Julien Sallais</dc:creator>
<dc:creator>Martin Post</dc:creator>
<dc:creator>Isabella Caniggia</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Placental Hypoxia-Induced Ferroptosis Drives Vascular Damage in Preeclampsia</dc:title>
<dc:identifier>pmid:39846172</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325119</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2024: the top 10 papers in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39844351/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 23:ehaf017. doi: 10.1093/eurheartj/ehaf017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39844351/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39844351</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf017>10.1093/eurheartj/ehaf017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39844351</guid>
<pubDate>Thu, 23 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:date>2025-01-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2024: the top 10 papers in heart failure</dc:title>
<dc:identifier>pmid:39844351</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf017</dc:identifier>
</item>
<item>
<title>Reply: Where the Definition of Fragility Came From and Where It Will Go</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e45-e46. doi: 10.1016/j.jacc.2024.10.120.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843038</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.120>10.1016/j.jacc.2024.10.120</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843038</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Mario Enrico Canonico</dc:creator>
<dc:creator>Rupert Bauersachs</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Where the Definition of Fragility Came From and Where It Will Go</dc:title>
<dc:identifier>pmid:39843038</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.120</dc:identifier>
</item>
<item>
<title>Where the Definition of Fragility Came From and Where It Will Go?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e43. doi: 10.1016/j.jacc.2024.09.1246.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843037</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1246>10.1016/j.jacc.2024.09.1246</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843037</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ruiting Jia</dc:creator>
<dc:creator>Yan Zhao</dc:creator>
<dc:creator>Aisong Zhu</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Where the Definition of Fragility Came From and Where It Will Go?</dc:title>
<dc:identifier>pmid:39843037</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1246</dc:identifier>
</item>
<item>
<title>Reply: Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e41. doi: 10.1016/j.jacc.2024.10.118.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843036</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.118>10.1016/j.jacc.2024.10.118</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843036</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Victoria L Bartlett</dc:creator>
<dc:creator>Michael Liu</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value</dc:title>
<dc:identifier>pmid:39843036</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.118</dc:identifier>
</item>
<item>
<title>Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e39-e40. doi: 10.1016/j.jacc.2024.08.089.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843035</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.089>10.1016/j.jacc.2024.08.089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843035</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kartik Giri</dc:creator>
<dc:creator>Aman Kakkar</dc:creator>
<dc:creator>Daniel Tarditi</dc:creator>
<dc:creator>Arthur C Lee</dc:creator>
<dc:creator>Maulik Shah</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value</dc:title>
<dc:identifier>pmid:39843035</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.089</dc:identifier>
</item>
<item>
<title>Reply: Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843034/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e37. doi: 10.1016/j.jacc.2024.10.119.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843034/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843034</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.119>10.1016/j.jacc.2024.10.119</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843034</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Karl-Philipp Rommel</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study</dc:title>
<dc:identifier>pmid:39843034</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.119</dc:identifier>
</item>
<item>
<title>Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843033/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):e35. doi: 10.1016/j.jacc.2024.08.090.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843033/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843033</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.090>10.1016/j.jacc.2024.08.090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843033</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Dawei Lin</dc:creator>
<dc:creator>Xiaochun Zhang</dc:creator>
<dc:creator>Wenzhi Pan</dc:creator>
<dc:creator>Daxin Zhou</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study</dc:title>
<dc:identifier>pmid:39843033</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.090</dc:identifier>
</item>
<item>
<title>Amara Yad Image: The Tricuspid Valve</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843032/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):295-296. doi: 10.1016/j.jacc.2024.12.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843032/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843032</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.026>10.1016/j.jacc.2024.12.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843032</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Amara Yad Image: The Tricuspid Valve</dc:title>
<dc:identifier>pmid:39843032</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.026</dc:identifier>
</item>
<item>
<title>The Amara Yad Project: A New Resource for Cardiac Anatomy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843031/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):292-294. doi: 10.1016/j.jacc.2024.12.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843031/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843031</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.007>10.1016/j.jacc.2024.12.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843031</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Amara Yad Project: A New Resource for Cardiac Anatomy</dc:title>
<dc:identifier>pmid:39843031</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.007</dc:identifier>
</item>
<item>
<title>Symptomatic Improvement "Only" in Unblinded Trials: The Plot Thickens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39843030/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250124051139&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28;85(3):247-249. doi: 10.1016/j.jacc.2024.11.045.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39843030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250124051139&v=2.18.0.post9+e462414">39843030</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.045>10.1016/j.jacc.2024.11.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39843030</guid>
<pubDate>Wed, 22 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexander M Levy</dc:creator>
<dc:creator>Jarmanjeet Singh</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2025-01-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Symptomatic Improvement "Only" in Unblinded Trials: The Plot Thickens</dc:title>
<dc:identifier>pmid:39843030</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.045</dc:identifier>
</item>





























</channel>
</rss>